Table 4.
Quartiles of soluble receptor for advanced glycation end products
|
Frequency distribution of CAD and control in sRAGE quartile categories
| |||||
|
sRAGE (pg/mL)
|
Group
|
Total
|
P
value
|
||
|
Case
|
Control
|
||||
| < 225 | n | 24 | 4 | 28 | 19.16/0.00b |
| % | 43.6 | 7.3 | 25.5 | ||
| ≥ 225-< 397.5 | n | 8 | 19 | 27 | 5.9/0.01a |
| % | 14.5 | 34.5 | 24.5 | ||
| ≥ 397.5-< 730 | n | 13 | 15 | 28 | 0.19/0.66 |
| % | 23.6 | 27.3 | 25.5 | ||
| ≥ 730 | n | 10 | 17 | 27 | 2.4/0.12 |
| % | 18.2 | 30.9 | 24.5 | ||
| Total | n | 55 | 55 | 110 | |
| % | 100.0 | 100.0 | 100.0 | ||
a
P < 0.05.
b
P < 0.01 (χ2 test).
CAD: Coronary artery disease; sRAGE: Soluble receptor for advanced glycation end products.